Nexien BioPharma is a development-stage pharmaceutical company with no revenue and no active operations. Nexien's core program targets myotonic dystrophy (DM), a genetic muscular disorder with no standard treatment, using cannabinoid-based drugs — primarily CBD and THC — as synthetic, FDA-regulated pharmaceuticals. All R&D has ceased due to lack of funding; the company has no employees, and officers serve without compensation. Nexien's primary asset is a granted U.S. patent covering a method to treat myotonia symptoms using a combination of CBD and THC, with corresponding European applications pending. A second patent application covers cannabinoid receptor modulators and terpenes to treat exposure to organophosphorus nerve agents, with a granted Israeli patent and pending applications in Europe and Canada. Nexien also holds a worldwide exclusive license from Accu-Break Pharmaceuticals for a proprietary cannabinoid drug delivery system, though the company has written down the value of this license due to financial constraints. In 2019, Nexien filed a pre-IND meeting request with the FDA for a CBD/THC sublingual tablet for DM and received written responses, but has not advanced to a formal IND filing. The DM indication may qualify for Orphan Drug designation. Nexien's current priority is finding a merger or acquisition target rather than advancing drug development independently.